CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 15 enrolled
Drug / intervention
oxycodone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00499460
NCT00499460Phase 4Completed
CompareCT.gov

Modulation of Opioid Effects by Garlic Supplements

Fred Hutchinson Cancer Center·interventional·Posted Jul 11, 2007·Updated Apr 7, 2017

In Brief

A Phase 4 clinical trial evaluating garlic powder tablets and oxycodone for Healthy, No Evidence of Disease. Completed, enrolled 15 participants across 1 site.

Detailed Summary

RATIONALE: Garlic supplements may alter the pharmacokinetics of oxycodone, thereby affecting its effectiveness as an opioid analgesic for the relief of moderate or severe pain. PURPOSE: This randomized phase 4 trial is studying how garlic supplements may change the pharmacokinetics of oxycodone and its analgesic and side effects in healthy volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy, No Evidence of Disease
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 11, 2007
Enrollment StartNov 1, 2006
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.0 years ago

Interventions

garlic powder tabletsdietary

Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet

oxycodonedrug

Single administration of three 5-mg oxycodone tablets or a 15-mg dose